Hot Investor Mandate: Paris-Based VC Firm Invests in Various Life Science Sectors, Focusing on Companies Located in France & Western Europe

25 Jun

A VC firm based in Paris invests primarily in seed/series A with significant follow-on capability.

The firm is now investing with two funds; the first fund is dedicated to investing in companies based in the Paris region across various sectors (digital, deeptech, life science), while the second fund is dedicated to investing in Digital Health companies in Western Europe. The firm generally invests between 0.3-1.5M EUR in the initial investment, and can invest up to 2-5M EUR overall in a company, and will invest in up to 10 companies a year.

The firm invests differently from their two current funds :

– The first fund is sector agnostic, and will invest in Life Science (therapeutics, diagnostics, devices and digital health companies) in the Paris region.
– The second fund covering Western Europe is focused primarily on digital health, due to the strategic interest of the fund investors in this area (several healthcare companies)

The firm can lead or co-invest, and do frequently lead. They will take a board seat in any case – the firm is an active investor providing hands-on support to its portfolio company (Strategy, HR, Financing, …).

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: USA Investment Firm Seeks Global Opportunities in Medical Devices, Diagnostics, and Digital Health, Investing Up to $10M

25 Jun

A venture capital firm founded in 2020 and based in USA is seeking opportunities in the medical devices, diagnostics, and digital health sectors of life sciences. The firm is looking to engage in Series A to Series B financing rounds with check sizes between 5 – 10 million USD. The firm prefers to lead the financing rounds but is open to co-investing. The firm will consider opportunities globally.

The firm is interested in early-stage opportunities in medical devices, diagnostics, and digital health sectors but does not invest in therapeutics. The firm is overall opportunistic and will consider various subsectors and indications. For digital health, the firm prefers b-to-b over b-to-c products. The firm will invest in all early-stage companies including pre and post commercial enterprises.

The firm seeks to work with management teams that have prior entrepreneurial experience. The firm prefers to lead financing rounds and will most likely take a board seat when leading. The firm considers themselves an active investor and will work closely with companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Fund Invests in Intersection of Technology & Life Science, Interested in Global Opportunities

25 Jun

A venture fund focusing on the intersection between technology and life sciences is willing to invest globally, investing in seed-series A stages, but will consider series B opportunities as well. The firm will generally invest between $0.5-2M in seed stages, $3-5M in series A rounds, and may invest up to $15M over the lifetime of the investment.

The firm invests in solutions to complex problems in human and animal health. The firm partners with entrepreneurs and academic scientists across all stages of venture investing, and its investments span the full continuum of the healthcare ecosystem. Previously funded companies include a microbiome-based drug discovery platform, a company sequencing T-cell receptors to analyze immune function and a company developing a continuous monitoring system using a dermal patch.

The firm remains actively involved in companies after investing. The firm generally takes a board seat or board observer position in their portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Calling All AI Investors and AI CEOs for Panelist Slots – 4D Meets AI Digital Conference September 17 -18

18 Jun

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Life Science Nation (LSN), through its Redefining Early Stage Investments (RESI) global conference series, has built an international partnering and funding infrastructure that helps investors source assets, and CEOs find capital and channel partners. LSN’s basic thesis is that having a conference once or twice a year doesn’t map well against the actual needs of doing business, and so it created the RESI conference series of partnering events taking place every couple of months to keep the dialogue moving. RESI facilitates early-stage life science players to develop new relationships, move along existing conversations or finalize the potential for a deal. This creates a vehicle to source, vet and finalize opportunities that fills a large gap in the life science arena, resulting in hundreds of companies that have been funded through the LSN network.

Extending the RESI partnering event by adding a standalone 4D Meets AI Digital Conference alongside RESI is a natural next step for LSN’s global partnering strategy. LSN’s current plan is to aggregate and embed new, cutting-edge, technologies into our global funding infrastructure to leverage the tsunami of new products and services emerging in the healthcare domain. If you are part of the Artificial Intelligence, Machine Learning, Big Data/-omics, Intelligent Agent, Smart Monitoring, Expert System, AI/Drug Development, AI Preclinical and Clinical, AI Imaging and Precision Medicine communities, and would like to participate as a panelist, please fill out the form below for this exciting opportunity. Please review the agenda below.

Preliminary Agenda Now Available
Accepting New Panelists!

 

Women In Bio CEOs Live Pitch Session from Digital RESI June

18 Jun

By Erich White, Business Development Manager, West Coast, LSN

Last Wednesday, June 10th, Women In Bio (WIB) sponsored a live pitch session during Digital RESI June that featured five companies led by women founders, followed by Q&A by a panel of five global investors. These companies had a chance to showcase their technology to a live audience, and to demonstrate their passion and commitment to their companies.

Watch a recording of the live session here

 

As part of their mission to support women in the life sciences, WIB sponsored this pitch session, to expose these women founders to as many global investors as possible. RESI served as a perfect partner, utilizing RESI’s global investor network that regularly participate in our events.

As an organizer of the WIB delegation, Sibylle Hauser, Chair WIB-Entrepreneur Center, commented, “RESI is a great conference and platform to gain women entrepreneurs exposure and experience. I really like the value of the feedback. A lot of these women entrepreneurs don’t get feedback on their approach or pitch from an investor’s point of view. So, the Digital RESI June pitch session is helping them hone in more and target their pitch to investors.”

Lisa Iadicicco, Executive Director of WIB added, “we wanted to create an event that would speak to a national audience and RESI and LSN offered a platform for us to do just that.”

During Digital RESI June last week, WIB’s sponsored pitch session featured:

  1. Andrea Wang, Co-founder & CEO of AHEAD Medicine
  2. Meesha Dogan, Co-founder & CEO of Cardio Diagnostic Inc.
  3. Eydis Lima, Founder & CEO of Dermadiagnostics
  4. Caitlin Cameron, Chair & CEO of OtoNexus Medical Technologies, Inc.
  5. Helena Cowley, CEO of Oxidien Pharmaceuticals

Digital RESI June Leading the Way in Digital Partnering – RESI Video Partnering Actually Works!

18 Jun

By Karen Deyo, Senior Investor Research Analyst, LSN

LSN continues to hold all-virtual RESI events, and each Digital RESI event surpasses the one before. At last week’s Digital RESI June Conference, we saw a record number of meetings taking place, with 2000+ meetings scheduled over three days across the globe. RESI logged over 800 hours of video conversations, as RESI attendees fit months of continuous meetings into a raucous three days of interactive dialogue. Digital RESI continues to provide a venue, albeit virtual, for investors and companies to connect, meet, maintain or transact business relationships. As with all RESI conferences, the 1:1 ratio of companies to investors promotes a lot of interaction, and, as the graph below shows, almost 80% of the meetings that took place were between companies and investors who were a fit for them. RESI continues to have a global reach, with people from all over the world connecting and participating in meetings, as demonstrated by the images below, depicting the partnering website traffic at different times.

Investors Are Doing Business As Usual

As many investors stressed in the panels recorded for RESI, they are still open for business, and RESI will continue to hold digital events to facilitate advancing relationships. Make sure to register for our upcoming 2-Day Dedicated Partnering Event, taking place July 27-28th, and our next Digital RESI, taking place Sept. 14-16th!

June 9th, 2020, at 3:00 a.m. Est

June 9th, 2020, at 9:00 a.m. Est

Hot Investor Mandate: USA Family Office Invests Up to $10M in Global Therapeutics Startups, with Strong Interests in Antibodies, Biologics, etc.

18 Jun

A family office with USA offices has a focus on the social impact as an overall investment mandate. The firm aims to fund cutting-edge therapeutics companies, through their accelerator arm while also investing in later-stage assets. The firm will invest globally. For their accelerator arm, the firm is seeking companies with pre-clinical and clinical therapeutics with a minimum initial investment of $1M-$10M, with the possibility of follow-on investments. The firm generally invests in companies with lead assets in Phase I – III clinical trials, and the amount of the allocation is based on the raise and pre-money valuation of the company.

The firm is looking for therapeutics companies, with a particular interest in biologics assets such as antibody-based technologies, cell and gene therapies. The firm mandate focused on regenerative and personalized medicine in oncology, neurodegenerative, orphan, and rare disease applications.

The firm will only consider companies that have more than two assets in the pipeline and experienced management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →